Novo Nordisk | pharmaphorum

Skip to main content

Thursday 24 September 2026

BlueSky linkedin youtube

header links

Get Newsletters
Media Kit

Pharmaphorum menu first category

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
Spotlight on
Events

close

SECTION

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
White Papers
Events

Channels

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

SUB NAVIGATION

Live Coverage
Partner Content
About us
Work for us
Contribute
Contact us
Advertise

Newsletters and Deep Dive digital magazine

youtube linkedin BlueSky

Novo Nordisk

News

Novo Nordisk HQ flag hires

Novo completes major filings for blockbuster hope semaglutid...

Novo Nordisk has its weekly diabetes hopeful semaglutide filed in five key markets, after submitting a dossier in Japan.

News

Roche Rituxan approval

Patient death raises concerns over Roche haemophilia drug

Concerns following event on HAVEN1 trial.

News

French pharma company Sanofi

Sanofi diabetes combo approved in EU

Drug will compete against Novo Nordisk's Xultophy.

News

Pfizer, Novo invest in Swedish patient stratification startup

Pfizer, Novo invest in Swedish patient stratification startu...

Funds will go towards development of AMRA's body composition profiling tool AMRA Profiler.

Views & Analysis

ces-2017

Digital health round-up – health innovations shine at CES 20...

A round-up of this week’s top digital healthcare news. Marco Ricci reports.

News

Red blood cells moving in blood vessels with depth of field.

Roche's haemophilia drug hits phase 3 targets

Roche hopes to take on Novo Nordisk and Shire.

Load more results

Editor's Picks

NICE finally backs Enhertu for HER2-low breast cancer

Novo Nordisk rebrands as Novo as new CEO charts turnaround

MPs seek probe into UK-US pharma deal's impact on NHS

FDA unveils framework for its expedited IND pilot

WCLC: Lung cancer news from BioNTech, Akeso, and Roche

News

AI specialists Enveda and Basecamp rake in the cash

AI specialists Enveda and Basecamp rake in the cash

AI-powered drug discovery companies Enveda and Basecamp have completed impressive funding rounds, worth $311m and $140m, respectively.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Digital

Discover a new era of healthcare panel engagement

Sponsored

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Pharmaphorum Menu

Digital
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Market Access
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Oncology
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Patients
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
R&D
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Sales & Marketing
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Spotlight on

Sign up for email newsletters and Deep Dive

Get Newsletters

youtube linkedin BlueSky

About us Advertising Contact us

Contribute Cookie Policy Privacy Policy

Terms & Conditions Work for us

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company